Research graph
References from Challenge‐Oriented Decision Tree for Analytical Method Selection in Metformin, Sodium–Glucose Cotransporter‐2 (SGLT2) Inhibitors and Dipeptidyl Peptidase‐4 (DPP‐4) Inhibitors Triple Antidiabetic Fixed‐Dose Combinations in Pharmaceutical Dosage Forms. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1155/2026/1129092
10.1155/2026/1129092 · External reference
10.2337/dc22‐s002
10.2337/dc22‐s002 · External reference
10.21608/ejchem.2024.161798.6953
10.21608/ejchem.2024.161798.6953 · External reference
10.1515/chem‐2025‐0230
10.1515/chem‐2025‐0230 · External reference
10.1039/c5ra17231d
10.1039/c5ra17231d · External reference
10.31838/ijpr/2020.12.04.702
10.31838/ijpr/2020.12.04.702 · External reference
Analytical Perspectives on Chromatographic Method Development for Impurity Profiling in Pharmaceuticals
2025 · External reference
10.1016/j.amjmed.2003.10.017
10.1016/j.amjmed.2003.10.017 · External reference
10.4158/ep.8.4.271
10.4158/ep.8.4.271 · External reference
Unresolved reference
External reference
10.1016/j.jpha.2013.09.003
10.1016/j.jpha.2013.09.003 · External reference
10.1007/s00216‐011‐5308‐5
10.1007/s00216‐011‐5308‐5 · External reference
10.1080/10408347.2023.2253321
10.1080/10408347.2023.2253321 · External reference
10.1002/sscp.70162
10.1002/sscp.70162 · External reference
Ion Pairing—Blessing or Curse
2008 · External reference
Unresolved reference
2017 · External reference
Unresolved reference
External reference
10.1590/s2175‐97902018000001006
10.1590/s2175‐97902018000001006 · External reference
10.1016/j.trac.2013.04.010
10.1016/j.trac.2013.04.010 · External reference
10.1177/15209156261449879
10.1177/15209156261449879 · External reference
10.1007/s00216‐012‐6197‐y
10.1007/s00216‐012‐6197‐y · External reference
10.1016/j.pharma.2021.06.003
10.1016/j.pharma.2021.06.003 · External reference
10.1093/chromsci/bmab030
10.1093/chromsci/bmab030 · External reference
10.1016/s0021‐9673(04)01152‐5
10.1016/s0021‐9673(04)01152‐5 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
10.52711/0974‐360x.2021.01011
10.52711/0974‐360x.2021.01011 · External reference
10.5958/2231‐5675.2020.00021.6
10.5958/2231‐5675.2020.00021.6 · External reference
10.22159/ajpcr.2022.v15i3.42117
10.22159/ajpcr.2022.v15i3.42117 · External reference
10.1007/978‐1‐60327‐043‐4_2
10.1007/978‐1‐60327‐043‐4_2 · External reference
10.1016/j.trac.2013.05.008
10.1016/j.trac.2013.05.008 · External reference
10.1098/rsos.220215
10.1098/rsos.220215 · External reference
Unresolved reference
2002 · External reference
10.52711/2231‐5675.2025.00007
10.52711/2231‐5675.2025.00007 · External reference
10.1016/s0021‐9673(01)01009‐3
10.1016/s0021‐9673(01)01009‐3 · External reference
10.25258/ijpqa.14.4.5
10.25258/ijpqa.14.4.5 · External reference
10.1201/noe0824727857‐254
10.1201/noe0824727857‐254 · External reference
10.9734/jpri/2021/v33i59a34326
10.9734/jpri/2021/v33i59a34326 · External reference
10.1186/s43094‐021‐00332‐1
10.1186/s43094‐021‐00332‐1 · External reference
10.1002/sscp.70235
10.1002/sscp.70235 · External reference
10.1155/2015/868727
10.1155/2015/868727 · External reference
10.1002/sscp.70155
10.1002/sscp.70155 · External reference
Development of a Stability‐Indicating RP‐HPLC Method for the Simultaneous Estimation of Metformin, Teneligliptin, and Dapagliflozin in Bulk and Combined Dosage Form
2026 · External reference
10.1016/j.talanta.2021.123046
10.1016/j.talanta.2021.123046 · External reference
10.1333/s00897242996a
10.1333/s00897242996a · External reference
10.7324/japs.2023.136050
10.7324/japs.2023.136050 · External reference
10.5530/ijper.56.4s.213
10.5530/ijper.56.4s.213 · External reference
10.5530/ijper.57.2.69
10.5530/ijper.57.2.69 · External reference
Unresolved reference
2013 · External reference
10.1080/10826076.2023.2284721
10.1080/10826076.2023.2284721 · External reference
10.1186/s13065‐025‐01620‐0
10.1186/s13065‐025‐01620‐0 · External reference
Unresolved reference
2011 · External reference
10.54037/wjps.2022.100905
10.54037/wjps.2022.100905 · External reference
10.1016/j.cpan.2026.03.007
10.1016/j.cpan.2026.03.007 · External reference
10.56530/lcgc.int.op2777i2
10.56530/lcgc.int.op2777i2 · External reference
10.56530/lcgc.int.ug8880n3
10.56530/lcgc.int.ug8880n3 · External reference
10.9734/jpri/2021/v33i61b35495
10.9734/jpri/2021/v33i61b35495 · External reference
Method Development of Metformin, Saxagliptin and Dapagliflozin in Marketed Formulations by HPLC
2022 · External reference
10.1016/j.clinbiochem.2004.11.007
10.1016/j.clinbiochem.2004.11.007 · External reference
10.1016/s0021‐9673(02)00205‐4
10.1016/s0021‐9673(02)00205‐4 · External reference
10.22159/ijap.2022v14i2.43626
10.22159/ijap.2022v14i2.43626 · External reference
Unresolved reference
2022 · External reference
10.1081/jlc‐200052969
10.1081/jlc‐200052969 · External reference
10.1002/bmc.5019
10.1002/bmc.5019 · External reference
10.1002/bmc.5384
10.1002/bmc.5384 · External reference
10.1208/s12248‐022‐00685‐2
10.1208/s12248‐022‐00685‐2 · External reference
10.1016/b978-0-323-95292-7.00016-5
10.1016/b978-0-323-95292-7.00016-5 · 2025 · External reference
10.1016/s0021‐9673(01)91570‐5
10.1016/s0021‐9673(01)91570‐5 · External reference
10.1002/jssc.202300571
10.1002/jssc.202300571 · External reference
Key Factors in Sample Diluent Selection for HPLC Assays of Active Pharmaceutical Ingredients
2005 · External reference
10.1111/dom.70197
10.1111/dom.70197 · External reference
